Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claudia Wellbrock

Showing results (1-10 of 54) with videos related to

Pageof 6
Sort By:
The New England Journal of Medicine|August 18, 2016
Melanoma and the Microenvironment--Age MattersClaudia Wellbrock
EMBO Molecular Medicine|July 16, 2015
Spatial intra-tumour heterogeneity in acquired resistance to targeted therapy complicates the use of PDX models for co-clinical cancer studiesClaudia Wellbrock
Biochemical Society Transactions|August 12, 2014
MAPK pathway inhibition in melanoma: resistance three waysClaudia Wellbrock
Pigment Cell & Melanoma Research|March 31, 2015
Microphthalmia-associated transcription factor in melanoma development and MAP-kinase pathway targeted therapyClaudia Wellbrock, Imanol Arozarena
The FEBS Journal|February 15, 2017
Targeting invasive properties of melanoma cellsImanol Arozarena, Claudia Wellbrock
Annals of Translational Medicine|November 9, 2017
Overcoming resistance to BRAF inhibitorsImanol Arozarena, Claudia Wellbrock
Frontiers in Cell and Developmental Biology|May 21, 2016
The Complexity of the ERK/MAP-Kinase Pathway and the Treatment of Melanoma Skin CancerClaudia Wellbrock, Imanol Arozarena
The Journal of Cell Biology|September 1, 2005
Elevated expression of MITF counteracts B-RAF-stimulated melanocyte and melanoma cell proliferationClaudia Wellbrock, Richard Marais
Pigment Cell & Melanoma Research|August 9, 2014
TP53 in the UV spotlight: a bona fide driver of melanomaAdam Hurlstone, Claudia Wellbrock
Nature Reviews. Cancer|June 19, 2019
Phenotype plasticity as enabler of melanoma progression and therapy resistanceImanol Arozarena, Claudia Wellbrock
Pageof 6

Showing results (1-10 of 54) with videos related to

Sort By:
Pageof 6
The New England Journal of Medicine|August 18, 2016
Melanoma and the Microenvironment--Age MattersClaudia Wellbrock
EMBO Molecular Medicine|July 16, 2015
Spatial intra-tumour heterogeneity in acquired resistance to targeted therapy complicates the use of PDX models for co-clinical cancer studiesClaudia Wellbrock
Biochemical Society Transactions|August 12, 2014
MAPK pathway inhibition in melanoma: resistance three waysClaudia Wellbrock
Pigment Cell & Melanoma Research|March 31, 2015
Microphthalmia-associated transcription factor in melanoma development and MAP-kinase pathway targeted therapyClaudia Wellbrock, Imanol Arozarena
The FEBS Journal|February 15, 2017
Targeting invasive properties of melanoma cellsImanol Arozarena, Claudia Wellbrock
Annals of Translational Medicine|November 9, 2017
Overcoming resistance to BRAF inhibitorsImanol Arozarena, Claudia Wellbrock
Frontiers in Cell and Developmental Biology|May 21, 2016
The Complexity of the ERK/MAP-Kinase Pathway and the Treatment of Melanoma Skin CancerClaudia Wellbrock, Imanol Arozarena
The Journal of Cell Biology|September 1, 2005
Elevated expression of MITF counteracts B-RAF-stimulated melanocyte and melanoma cell proliferationClaudia Wellbrock, Richard Marais
Pigment Cell & Melanoma Research|August 9, 2014
TP53 in the UV spotlight: a bona fide driver of melanomaAdam Hurlstone, Claudia Wellbrock
Nature Reviews. Cancer|June 19, 2019
Phenotype plasticity as enabler of melanoma progression and therapy resistanceImanol Arozarena, Claudia Wellbrock
Pageof 6